Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$97.83 USD

97.83
16,833,817

-0.40 (-0.41%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $97.76 -0.07 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (151 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio

by Zacks Equity Research

AVNS acquires Nexus Medical, adding its TKO connector to expand critical care offerings and drive immediate revenue and earnings growth.

Zacks Equity Research

Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy

by Zacks Equity Research

ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.

Zacks Equity Research

CAH Strengthens Distribution With New Consumer Health Logistics Hub

by Zacks Equity Research

Cardinal Health opens a 350,000-square-foot Consumer Health Logistics Center in Ohio, strengthening its pharmaceutical supply chain and advancing its multiyear infrastructure expansion strategy.

Zacks Equity Research

GEHC Expands Women's Health Portfolio With AI-Enabled Voluson

by Zacks Equity Research

GE HealthCare debuts AI-powered Voluson Performance ultrasound systems, enhancing women's health imaging with faster, smarter diagnostics.

Zacks Equity Research

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

Zacks Equity Research

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Boston Scientific (BSX) settling at $105.23, representing a -2.65% change from its previous close.

Zacks Equity Research

Reasons to Retain Avanos Medical Stock in Your Portfolio Now

by Zacks Equity Research

AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.

Zacks Equity Research

Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System

by Zacks Equity Research

MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.

Zacks Equity Research

Cardinal Health Expands At-Home Solutions With New Texas Facility

by Zacks Equity Research

CAH announces the opening of a new distribution center in Texas, which is likely to support its at-Home Solutions business.

Zacks Equity Research

GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System

by Zacks Equity Research

GE HealthCare's FDA-cleared Revolution Vibe CT promises faster, AI-driven cardiac imaging with improved clarity, boosting efficiency and patient comfort.

Zacks Equity Research

PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq

by Zacks Equity Research

PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools.

Zacks Equity Research

Here's Why You Should Hold Cencora Stock in Your Portfolio Now

by Zacks Equity Research

COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

by Zacks Equity Research

ECL's strong Q2 results, innovation pipeline, and high-tech growth drivers support its long-term expansion despite macro headwinds.

Zacks Equity Research

HealthEquity Stock Gains as Q2 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

HQY's Q2 results reflect EPS growth of 25.6% year over year, revenue growth of 8.6% and a 12% increase in HSA. The company also updates its fiscal 2026 guidance.

Zacks Equity Research

Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Boston Scientific (BSX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

STXS Launches First U.S. Robotic HD Mapping With MAGiC Sweep

by Zacks Equity Research

Stereotaxis debuts MAGiC Sweep, the first U.S. robotic HD mapping catheter, marking a breakthrough in cardiac arrhythmia diagnosis and treatment.

Zacks Equity Research

Boston Scientific (BSX) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $106.66, marking a +1.1% move from the previous day.

Zacks Equity Research

IRTC Unveils Positive AMALFI Trial Data Showing Higher AF Detection

by Zacks Equity Research

iRhythm's AMALFI trial shows its Zio monitoring service boosts AF detection and speeds diagnosis, strengthening its edge in cardiac care.

Zacks Equity Research

GEHC Launches AI-Powered Vivid Pioneer Cardiac Ultrasound System

by Zacks Equity Research

GE HealthCare's Vivid Pioneer, cleared by CE Mark and FDA, brings AI-powered speed, precision and efficiency to cardiac imaging.

Zacks Equity Research

Reasons to Retain TransMedics Stock in Your Portfolio for Now

by Zacks Equity Research

TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.

Zacks Equity Research

COO Q3 Earnings Beat, 2025 Sales Outlook Lowered, Stock Down

by Zacks Equity Research

Cooper Companies beats on Q3 earnings with 15% EPS growth, but revenue weakness and a trimmed 2025 outlook send shares tumbling.

Zacks Equity Research

Here's Why You Should Add CLOV Stock to Your Portfolio Now

by Zacks Equity Research

Clover's strong membership growth, rising revenues, and first-half EBITDA profitability highlight its tech-driven Medicare Advantage edge.

Zacks Equity Research

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.

Moumi Mondal headshot

The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?

by Moumi Mondal

HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.